(Meningococcal [serotypes A, C, W-135, X, Y] (pentavalent) vaccine is under clinical development by Serum Institute of India and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect (Meningococcal [serotypes A, C, W-135, X, Y] (pentavalent) vaccine’s likelihood of approval (LoA) and phase transition for Meningitis took place on 28 Oct 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their (Meningococcal [serotypes A, C, W-135, X, Y] (pentavalent) vaccine Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

(Meningococcal [serotypes A, C, W-135, X, Y] (pentavalent) vaccine overview

Vaccine candidate is under development for the prevention of meningitis. The vaccine candidate is a pentavalent meningococcal conjugate vaccine (A, C, Y, W-135, X). It is administered by intramuscular route. The vaccine comprises of MenX capsular polysaccharide (PS) that is conjugated to tetanus toxoid, it is also formulated as thermostable.

Serum Institute of India overview

Serum Institute of India (Serum Institute), a subsidiary of Cyrus Poonawalla Group, is a biotechnology company that manufactures and supplies vaccines and immuno-biologicals to treat polio, diphtheria, tetanus, pertussis, r-hepatitis B, measles, mumps and rubella. The company’s product portfolio includes bacterial, viral, covid, influenza, polysaccharide conjugate and combination vaccines; recombinant and pharma products; and anti-sera vaccines. It markets the Oxford–AstraZeneca COVID-19 vaccine under the brand name Covishield in India. It is investigating DTaP, an acellular vaccine against pertussis; pentavalent meningococcal conjugate vaccine to prevent epidemic group A meningococcal disease; ErepoXen, to maintain red blood cell production and prevent anemia caused by chronic kidney failure; and HPV vaccine against cervical cancer. Serum Institute is headquartered in Pune, Maharashtra, India

Quick View (Meningococcal [serotypes A, C, W-135, X, Y] (pentavalent) vaccine LOA Data

Report Segments
  • Innovator
Drug Name
  • (Meningococcal [serotypes A, C, W-135, X, Y] (pentavalent) vaccine
Administration Pathway
  • Intramuscular
Therapeutic Areas
  • Infectious Disease
Key Developers
  • Sponsor Company: Serum Institute of India
  • Originator: Serum Institute of India
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.